Novo says Victoza bests MSD’s Januvia at lowering blood sugar
Novo Nordisk says its diabetes drug Victoza, in combination with metformin, outperformed MSD’s Januvia plus metformin in reducing HbA1c – a measure of high blood sugar.
The 26-week 407-patient LIRA-SWITCH trial assessed the effects of switching from Januvia (sitagliptin) plus metformin to Victoza (liraglutide) plus metformin.
The study showed that patients who switched to Victoza achieved a superior reduction in HbA1c compared to those who remained on Januvia: 1.14% versus 0.54%.
Additionally, adults who switched to Victoza experienced significantly greater body weight reductions compared to those who continued with their sitagliptin dose – at 3.31 kg versus 1.64 kg.
“The LIRA-SWITCH trial results provide valuable insight that adults uncontrolled on sitagliptin may achieve a superior HbA1c reduction with liraglutide 1.8 mg versus continuing on sitagliptin treatment,” says Dr Maximo Maislos, director of Western Negev Mobile Diabetes Clinic Program, and investigator of the LIRA-SWITCH trial. “These findings are valuable, as there is limited clinical evidence to guide treatment strategy when people with type 2 diabetes are uncontrolled on second-line therapy.”
More adults with type 2 diabetes treated with Victoza achieved their HbA1c targets, compared to those on sitagliptin, at 50.6% versus 26.9%. Victoza patients also demonstrated significantly greater reductions in fasting plasma glucose vs those treated with sitagliptin: 1.84 versus 0.73.
Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing …
Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent …